跳至主要内容
临床试验/EUCTR2009-017011-16-SE
EUCTR2009-017011-16-SE进行中(未招募)不适用

Treatment of the low IGF-1 syndrome associated with Chronic Heart Failure: A Randomized, Placebo-Controlled, Double-Blind Study

niversity Federico II0 个研究点开始时间: 2011年5月4日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Patients of either sex affected by CHF NYHA class II-III, secondary to ischemic or idiopathic dilated cardiomyopathy
  • Age range 30-80 years
  • Stable medications for at least two months prior to randomization, including ACE inhibitors or AT1 antagonists and beta-blockers (unless untolerated).
  • LV ejection fraction 40% or less
  • Peak VO2 consumption during a CPET = 16 ml/kg/min.
  • LV end-diastolic dimension 55 mm or more
  • Low IGF-1 levels and a satisfactory response to an IGF-1 generation test (see below)
  • Positive result after GH-provocation test (PD-GHRH; cut-off GH levels defined as 18.3, 9.0, and 5.0 mg/l for normal weight, overweight and obese subjects respectively)
  • Informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 84
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 84

排除标准

  • Haemodynamic clinically significant primary valvular disease or significant congenital heart disease
  • Acute pericarditis/myocarditis
  • Inability to perform a bicycle exercise test
  • Poorly controlled diabetes mellitus (HbA1c >8.5)
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Active and/or history of malignancy
  • Evidence of progression or recurrence of an underlying intracranial tumor
  • Unstable angina or recent myocardial infarction (less than 5 months)
  • Severe liver disease
  • Serum creatinine levels >2.5 mg/dl
  • Inability to cooperate or administer the study drug
  • Patients participating in any other clinical study, within 30 days prior to screening visit and/or during this particular study period
  • With regard to inclusion criterion no. 7, an IGF-1 level will be considered low if below the 25th percentile of a sex and age matched population (33-35). The following cut-off values will be used: 130 ng/ml (age 30-39 y); 115 ng/ml (age 40-49 y); 105 ng/ml (age 50-59 y); 95 ng/ml (age 60-69 y); 85 ng/ml (age 70-80 y).

研究者

发起方
niversity Federico II

相似试验